loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

Themis Medicare Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Themis Medicare Ltd. 25 Aug 2026 16:04 PM

Q1FY27 Quarterly Result Announced for Themis Medicare Ltd.

Pharmaceuticals company Themis Medicare announced Q1FY27 results

Consolidated Financial Highlights:

  • Revenue from Operations: The consolidated revenue for Q1FY27 stood at Rs 8,695.69 lakh, representing a growth of 13.62% from Rs 7,653.05 lakh in Q4FY26 (QoQ) and a decline of 10.88% from Rs 9,757.77 lakh in Q1FY26 (YoY).
  • Total Income: The company reported a total income of Rs 8,795.06 lakh in Q1FY27, showing a 9.67% increase compared to Rs 8,019.75 lakh in Q4FY26 (QoQ). On a YoY basis, total income decreased by 10.94% from Rs 9,875.36 lakh in Q1FY26.
  • Net Profit for the Period: The company recorded a net profit of Rs 2,461.14 lakh in Q1FY27, reflecting a growth of 176.99% from Rs 888.54 lakh in Q4FY26 (QoQ). This performance marks a significant turnaround compared to a net loss of Rs 1,421.97 lakh in Q1FY26 (YoY).
  • Total Comprehensive Income: Total comprehensive income for Q1FY27 was Rs 2,442.79 lakh, compared to Rs 882.51 lakh in Q4FY26 (QoQ) and a comprehensive loss of Rs 1,424.77 lakh in Q1FY26 (YoY).
  • Earnings Per Share (EPS): The basic and diluted EPS for Q1FY27 was Rs 2.67, up from Rs 0.96 in Q4FY26 and an improvement from a negative Rs (1.54) in Q1FY26.
  • Exceptional Item: During Q1FY27, the company recorded an exceptional profit of Rs 9,295.34 lakh on the sale of shares.

Standalone Financial Highlights:

  • Revenue from Operations: Standalone revenue for Q1FY27 was Rs 8,695.69 lakh, increasing by 13.62% from Rs 7,653.05 lakh in Q4FY26 (QoQ) but decreasing by 10.88% from Rs 9,757.77 lakh in Q1FY26 (YoY).
  • Total Income: Standalone total income for Q1FY27 stood at Rs 8,795.06 lakh, a 9.67% growth over Rs 8,019.75 lakh in Q4FY26 (QoQ) and a 10.94% decline from Rs 9,875.36 lakh in Q1FY26 (YoY).
  • Net Profit for the Period: The standalone net profit for Q1FY27 reached Rs 2,873.72 lakh, showing a substantial increase of 1,362.01% compared to Rs 196.56 lakh in Q4FY26 (QoQ). The company had reported a net loss of Rs 1,537.37 lakh in Q1FY26 (YoY).
  • Profit Before Tax: Profit before tax for Q1FY27 was Rs 4,272.33 lakh, significantly higher than Rs 213.58 lakh in Q4FY26 (QoQ). The profit was bolstered by an exceptional item of Rs 9,966.79 lakh.
  • Earnings Per Share (EPS): Basic and diluted EPS for the standalone entity was Rs 3.12 in Q1FY27, compared to Rs 0.21 in Q4FY26 and Rs (1.67) in Q1FY26.

Business Highlights:

  • Sale of Investment: During Q1FY27, the company sold 24,97,190 equity shares of its investment in Gujarat Themis Biosyn Limited, an Associate Company, for a total consideration of Rs 100 crore.
  • Exceptional Gains: The profit on the sale of the aforementioned investment amounted to Rs 99.67 crore on a standalone basis and Rs 92.95 crore on a consolidated basis.
  • Subsidiary Dissolution: The company’s wholly owned subsidiary, Carpo Medicals Limited (UK), was dissolved effective from April 14, 2025. The company has provided for the investment of Rs 0.76 lakh and receivables/advances of Rs 128.63 lakh related to this subsidiary as an exceptional item in the financial statements.
  • Corporate Changes: The Board approved the appointment of Mr. Suresh Savaliya as the Company Secretary, Compliance Officer, and Key Managerial Personnel (KMP) effective August 13, 2026, following the resignation of Mr. Nagraj Mogaveera.

Result PDF

Pharmaceuticals company Themis Medicare announced Q4FY26 & FY26 results

Q4FY26 Consolidated Financial Highlights:

  • Revenue from Operations: Stood at Rs 7,653.05 lakh in Q4FY26, registering a growth of 6.73% YoY compared to Rs 7,170.16 lakh in Q4FY25. On a QoQ basis, it witnessed a decline of 15.09% from Rs 9,013.32 lakh in Q3FY26.
  • Total Income: Reported at Rs 8,019.75 lakh in Q4FY26, marking an increase of 9.48% YoY against Rs 7,325.35 lakh in Q4FY25, but a decrease of 12.27% QoQ compared to Rs 9,141.55 lakh in Q3FY26.
  • Profit for the Period (PAT): Reached Rs 888.54 lakh in Q4FY26, showing a strong turnaround from a loss of Rs 966.45 lakh in Q4FY25. Sequentially, PAT declined by 11.97% QoQ from Rs 1,009.36 lakh in Q3FY26.

FY26 Consolidated Financial Highlights:

  • Revenue from Operations: Recorded at Rs 34,223.55 lakh for FY26, reflecting a decline of 15.60% YoY compared to Rs 40,551.16 lakh in FY25.
  • Total Income: Stood at Rs 35,159.71 lakh in FY26, a decrease of 14.28% YoY from Rs 41,018.11 lakh in FY25.
  • Profit for the Period (PAT): Plunged by 96.17% YoY to Rs 114.37 lakh in FY26, down from a profit of Rs 2,983.28 lakh in FY25.

Q4FY26 Standalone Financial Highlights:

  • Revenue from Operations: Stood at Rs 7,653.05 lakh in Q4FY26, an increase of 6.73% YoY compared to Rs 7,170.16 lakh in Q4FY25, but down by 15.09% QoQ from Rs 9,013.32 lakh in Q3FY26.
  • Total Income: Was Rs 8,019.75 lakh in Q4FY26, reflecting a YoY growth of 9.48% from Rs 7,325.35 lakh in Q4FY25. On a QoQ basis, it decreased by 12.27% from Rs 9,141.55 lakh in Q3FY26.
  • Profit for the Period (PAT): Reported a profit of Rs 196.56 lakh in Q4FY26, recovering from a loss of Rs 774.48 lakh in Q4FY25. However, it saw a QoQ decline of 57.07% from Rs 457.81 lakh in Q3FY26.

FY26 Standalone Financial Highlights:

  • Revenue from Operations: Reached Rs 34,223.55 lakh for FY26, marking a decrease of 15.60% YoY from Rs 40,551.16 lakh in FY25.
  • Total Income: Stood at Rs 35,159.71 lakh in FY26, a drop of 14.28% YoY compared to Rs 41,018.11 lakh in FY25.
  • Profit for the Period (PAT): The company reported a net loss of Rs 1,418.55 lakh in FY26, sliding from a net profit of Rs 2,392.15 lakh reported in FY25.

Business Highlights:

  • Segment Performance: The Company operates in a single business segment, i.e., Pharmaceuticals, and hence does not have any separately reportable business segments.
  • Dividend Recommendation: The Board of Directors has recommended a final dividend of Re 0.50 per fully paid-up equity share (50% on the face value of Re 1/- each), aggregating to Rs 4,60,50,060 for the financial year ended 31st March, 2026, subject to the approval of shareholders.
  • Exceptional Items: The company presented an incremental regulatory impact of Rs 86.53 lakh under Exceptional Items in its Q3FY26 results due to changes in the new Labour Codes. Additionally, in the standalone results, an exceptional item of Rs 129.39 lakh was noted, relating to investments, receivables, and advances for its wholly-owned dissolved UK subsidiary, M/s. Carpo Medicals Limited, which the company is in the process of writing off pending RBI approval.

Result PDF

Pharmaceuticals company Themis Medicare announced Q2FY26 results

  • Revenue: Rs 78.0 crore against Rs 117.0 crore during Q2FY25.
  • EBITDA: Rs -3.1 crore against Rs 17.1 crore during Q2FY25.
  • EBITDA Margin: -4.0% for Q2FY26.
  • PAT: Rs -3.6 crore against Rs 14.3 crore during Q2FY25.
  • PAT Margin: -4.6% for Q2FY26.
  • EPS: Rs -0.39 for Q2FY26.

Sachin Patel, Managing Director & CEO, said: “The Company continued to face headwinds from disruption in a high margin major line of Business since the last two quarters. In this regard, regulators are currently investigating the matter and we expect a positive development on this by March 2026.

Despite the headwinds, our API business grew 31% year-on-year in the half-year period, while Trade business increased 4%. As part of our Hospital business, we aim to increase our focus on high margin brands and products.

Moving forward, we are striving to improve operational efficiency, cost optimization, field force productivity, and working capital management. Our R&D pipeline continues to be strong, and we will keep directing our efforts into creating differentiated products in critical therapeutic areas.

Consolidated revenue for the quarter was reported at Rs 78 crore; muted performance in the formulations business hampered profitability. The Company remains resilient and we are cautiously optimistic based on our core competence and overall market opportunity.”

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Get it on google Play Store Download on the App Store
market app